Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85023
- Arizona Research Center
-
Phoenix, Arizona, United States, 85004
- Dba 21st Century Neurology
-
-
California
-
Anaheim, California, United States, 92801
- Advanced Clinical Research Institute
-
Anaheim, California, United States, 92801
- Orange County Clinical Trials
-
Fair Oaks, California, United States, 95628
- Med Investigations, Inc.
-
Northridge, California, United States, 91325
- Northridge Neurological Center
-
Pismo Beach, California, United States, 93449
- Arroyo Medical Group, Inc.
-
Sacramento, California, United States, 95821
- Northern California Research
-
Sacramento, California, United States, 95825
- Superior Research, LLC
-
Santa Ana, California, United States, 92705
- Apex Research Institute
-
-
Florida
-
Fort Meyers, Florida, United States, 33916
- Clinical Physiology Associates Clinical Study
-
Orlando, Florida, United States, 32806
- Compass Research
-
-
Indiana
-
South Bend, Indiana, United States, 46601
- Memorial Medical Group - Clinical Research
-
-
Kentucky
-
Bowling Green, Kentucky, United States, 42101
- Graves Gilbert Clinic
-
Madisonville, Kentucky, United States, 42431
- Commonwealth Biomedical Resaerch, LLC
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Louisiana Sleep Foundation
-
-
Michigan
-
Interlochen, Michigan, United States, 49643
- Professional Clinical Research - Interlochen
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Quality Clinical Research, Inc
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Albuquerque Neuroscience, Inc.
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- The Center for Clinical Research
-
-
Ohio
-
Cincinnati, Ohio, United States, 45224
- Hill Top Physicians Inc. / Hihgtop Medical Research Center
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Altoona Center for Clinical Research
-
Mechanicsburg, Pennsylvania, United States, 17055
- Central Pennsylvania Clinic
-
-
South Carolina
-
Columbia, South Carolina, United States, 29204
- Southern Orthopeadic Sports
-
Rock Hill, South Carolina, United States, 29732
- The Carolina Center for Rheumatology & ArthiritisCare PA
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37421
- ClinSearch
-
-
Texas
-
Austin, Texas, United States, 78756
- FutureSearch Trials of Neurology
-
Fort Worth, Texas, United States, 76108
- DFW Wellness
-
Houston, Texas, United States, 77063
- Houston Sleep Clinic
-
San Antonio, Texas, United States, 78215
- Sun Research Institute
-
Sugar Land, Texas, United States, 77479
- Clinical Health Research, LLC
-
-
Washington
-
Renton, Washington, United States, 98055
- Pacific Rheumatology Associates
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is able to understand the written informed consent
- Subject is 18 years of age or older.
- Subject meets the ACR criteria for fibromyalgia
- Subject is willing to discontinue prohibited by the protocol
- Subject agrees to use only non-sedating over-the-counter (OTC)medication
- Subject is willing to abstain from the ingestion of alcohol for the duration of the trial.
Exclusion Criteria:
- Subject has protocol prohibited medical & psychiatric conditions that would exclude subject
- Subject has a current or past history of a substance use disorder including alcohol abuse
- Subject has a clinically significant history of seizure disorder either past or present
- Female subject who is pregnant, nursing or lactating.
- Subject is diagnosed with sleep apnea
- Subject is unable to discontinue protocol prohibited medications
- Subject is experiencing fatigue and/or drowsiness/sedation in association with intake of allowed medications.
- Subject has taken any investigational drug within 5 half-lives of the investigational drug prior to signing the informed consent form.
- Subject has an allergic reaction to GHB or sodium oxybate or any of its constituents (e.g. malic acid).
- Subject is on a sodium-restricted diet.
- Subject has abnormal liver function test or other abnormal lab values
- Subject has an occupation that requires variable shift work or routine night shifts or cannot routinely spend at least 6 hours per night in bed.
- Subject has any other problems that, in the investigator's opinion, would preclude the subject's participation and completion of this trial or compromise reliable representation of subjective symptoms.
- Subject has been randomized into a previous Xyrem (sodium oxybate) clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: 1
Sodium Oxybate Oral Solution (4.5 grams)
|
4.5 grams per night taken in two equally divided doses
|
|
EXPERIMENTAL: 2
Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (4.5 grams)
|
4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
|
|
EXPERIMENTAL: 3
Sodium Oxybate Oral Solution (6 grams)
|
6 grams per night taken in two equally divided doses
|
|
EXPERIMENTAL: 4
Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (6 grams)
|
6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Summary of Most Frequent Adverse Events (Per Arm) Experienced by Study Subjects
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Tolerability Assessed by Adverse Events
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Fibromyalgia
- Myofascial Pain Syndromes
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Adjuvants, Anesthesia
- Sodium Oxybate
Other Study ID Numbers
Other Study ID Numbers
- 08-004 (Other Identifier: Prostate Cancer Clinical Trials Consortium Protocol Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.